Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 162Leukemia 43Lymphoma 42Multiple Myeloma 39Leukemia, Lymphocytic, Chronic, B-Cell 39Neoplasms, Plasma Cell 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Non-Hodgkin 35Lymphoma, Mantle-Cell 35Lymphoma, Large-Cell, Immunoblastic 35Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Follicular 35Monoclonal Gammopathy of Undetermined Significance 34Burkitt Lymphoma 34Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 33Lymphoma, B-Cell, Marginal Zone 33Myeloproliferative Disorders 32Myelodysplastic Syndromes 32Leukemia, Myeloid, Acute 32Hodgkin Disease 32Immunoblastic Lymphadenopathy 31Lymphoma, Large-Cell, Anaplastic 30Immunoglobulin Light-chain Amyloidosis 30Waldenstrom Macroglobulinemia 29Primary Myelofibrosis 29Thrombocythemia, Essential 28Leukemia, Hairy Cell 28Leukemia, Biphenotypic, Acute 28Lymphoma, T-Cell, Cutaneous 27Leukemia, Prolymphocytic 27

Interventions

venetoclax 1fludarabine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Venentoclax × Other neoplasm × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡